Pfizer Inc (PFE): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Pfizer ( PFE) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 2.5%. By the end of trading, Pfizer rose $0.71 (2.2%) to $32.69 on average volume. Throughout the day, 25,881,830 shares of Pfizer exchanged hands as compared to its average daily volume of 26,377,500 shares. The stock ranged in a price between $32.34-$32.74 after having opened the day at $32.37 as compared to the previous trading day's close of $31.98. Other companies within the Drugs industry that increased today were: Rosetta Genomics ( ROSG), up 26.5%, Egalet ( EGLT), up 16.0%, Corcept Therapeutics ( CORT), up 15.7% and China Pharma ( CPHI), up 14.9%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $208.1 billion and is part of the health care sector. Shares are up 4.4% year to date as of the close of trading on Monday. Currently there are 8 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Pfizer as a buy. The company's strengths can be seen in multiple areas, such as its increase in stock price during the past year, impressive record of earnings per share growth and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the negative front, Bioline Rx ( BLRX), down 13.0%, Atossa Genetics ( ATOS), down 11.3%, OvaScience ( OVAS), down 9.5% and Aoxing Pharmaceutical Company ( AXN), down 7.8% , were all laggards within the drugs industry with Theravance ( THRX) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Boeing Is Back to Cruising Altitude; GM Gets Assist From Amazon -- ICYMI

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Aceto's Search for Deal May Be Slowed by DOJ Subpoena

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Dow and S&P 500 Finish Higher Amid Strong Corporate Earnings

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk

Veteran Foreign Affairs Expert Ian Bremmer Reveals How to Price Political Risk